Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-16-000098
Filing Date
2016-08-10
Accepted
2016-08-10 07:41:02
Documents
39
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20160630x10q.htm 10-Q 896381
2 EX-31.1 c617-20160630xex31_1.htm EX-31.1 15144
3 EX-31.2 c617-20160630xex31_2.htm EX-31.2 15353
4 EX-32.1 c617-20160630xex32_1.htm EX-32.1 11719
5 GRAPHIC c617-20160630x10qg001.jpg GRAPHIC 18865
  Complete submission text file 0000926617-16-000098.txt   2784327

Data Files

Seq Description Document Type Size
6 EX-101.INS c617-20160630.xml EX-101.INS 413045
7 EX-101.SCH c617-20160630.xsd EX-101.SCH 23228
8 EX-101.CAL c617-20160630_cal.xml EX-101.CAL 31233
9 EX-101.DEF c617-20160630_def.xml EX-101.DEF 76834
10 EX-101.LAB c617-20160630_lab.xml EX-101.LAB 191765
11 EX-101.PRE c617-20160630_pre.xml EX-101.PRE 159685
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 161819980
SIC: 2835 In Vitro & In Vivo Diagnostic Substances